Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris

American Journal of Clinical Dermatology

Volumn 8, Issue 2, 2007, Pages 85-92

  Olszewska, Malgorzata ^a,c   Kolacinska Strasz, Zofia ^a   Sulej, Jadwiga ^a   Labecka, Hanna ^a   Cwikla, Jaroslaw ^b   Natorska, Urszula ^a   Blaszczyk, Maria ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Radiology Unit   (Poland)

^c NONE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; PREDNISONE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ADJUVANT THERAPY; ADULT; AGED; AMENORRHEA; ANTIBODY DETECTION; ARTICLE; BACTERIAL INFECTION; BLADDER CANCER; BREAST CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHING SYNDROME; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; HYPERTRICHOSIS; IMMUNE STATUS; INCIDENCE; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; MOUTH MUCOSA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; SKIN; SKIN CANCER; SKIN INFECTION; STROKE; THROMBOCYTOPENIA; THRUSH; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; CHILD; DRUG COMBINATION; MIDDLE AGED; PEMPHIGUS; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; CHILD; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PEMPHIGUS; PREDNISONE; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34250658145     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200708020-00004     Document Type: Article

References (36)

1. Bystryn JC. How should pemphigus be treated? J Eur Acad Dermatol Venereol 2002 Nov; 16 (6): 562-3
2. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. Arch Dermatol 1996 Feb; 132 (2): 203-12
3. Ahmed AR, Moy R. Death in pemphigus. J Am Acad Dermatol 1982 Aug; 7 (2): 221-8
4. Mimouni D, Anhalt GJ. Pemphigus. Dermatol Ther 2002; 15: 362-8
5. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003 Nov; 149 (5): 926-37
6. Mimouni D, Nousari CH, Cummins DL, et al. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol 2003 Dec; 49 (6): 1059-62
7. Yeh SW, Sami N, Ahmed AR. Treatment of pemphigus vulgaris: current and emerging options. Am J Clin Dermatol 2005; 6 (5): 327-42
8. Dick SE, Wert VP. Pemphigus: a treatment update. Autoimmunity 2006 Nov; 39 (7): 591-9
9. Mimouni D, Anhalt GJ, Cummins DL, et al. Treatment of pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol 2003 Jun; 139 (6): 739-42
10. Stanley JR. Therapy of pemphigus vulgaris. Arch Dermatol 1999 Jan; 135 (1): 76-7
11. Korman N. Pemphigus. J Am Acad Dermatol 1988 Jun; 18 (6): 1219-38
12. Lapidoth M, David M, Ben-Amital D, et al. The efficacy of combined treatment of prednisone and cyclosporine in patients with pemphigus: preliminary study. J Am Acad Dermatol 1994 May; 30 (5 Pt 1): 752-7
13. Shah N, Green AR, Elgart GW, et al. The use of chlorambucil with prednisone in the treatment of pemphigus. J Am Acad Dermatol 2000 Jan; 42 (1 Pt 1): 85-8
14. Benoit Corven C, Carvalho P, Prost C, et al. Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme) [in French]. Ann Dermatol Venereol 2003 Jan; 130 (1 Pt 1): 13-5
15. Cummins DL, Mimouni D, Anhalt GJ, et al. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol 2003 Aug; 49 (2): 276-80
16. Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol 2000 Dec; 43 (6): 1065-9
17. Nousari CH, Brodsky R, Anhalt GJ. Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol 2003 Jul; 49 (1): 148-50
18. Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000 Jul; 136 (7): 868-72
19. Ebringer A, Mackay IR. Pemphigus vulgaris successfully treated with cyclophosphamide. Ann Intern Med 1969 Jul; 71 (1): 125-7
20. Fellner MJ, Katz JM, McCabe JB. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris. Arch Dermatol 1978 Jun; 114 (6): 889-94
21. Sysa-Jedrzejowska A, Lutowiecka-Wranicz A. Czy pecherzyca zwykla jest choroba uleczalna? Przegl Dermatol 1991; 68: 284-8
22. Kazlow Stern D, Tripp JM, Ho VC, et al. The use of systemic immune moderators in dermatology: an update. Dermatol Clin 2005 Apr; 23 (2): 259-300
23. Bhat R, Sharma VR, Ramam M, et al. Cyclophosphamide pulses with oral prednisolone in the treatment of pemphigus: a pilot study. Dermatol Online J 2005 Dec; 11 (3): 4
24. Fleishii ME, Valek RH, Pandya AG. Pulse intravenous cyclophosphamide therapy in pemphigus. Arch Dermatol 1999 Jan; 135 (1): 57-61
25. Pandya AG, Sontheimer RD. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol 1992 Dec; 128 (12): 1626-30
26. Pasricha JS, Khaitan BK, Raman RS, et al. Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995; 34 (12): 875-82
27. De Horatius DM, Sperber BR, Werth VP. Glucocorticoids in the treatment of bullous diseases. Dermatol Ther 2002; 15: 298-310
28. Volkmer BG, Seidl-Schlick EM, Bach D, et al. Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma. Clin Rheumatol 2005 Aug; 24 (4): 319-23
29. Tanguaya C, Harvey I, Houde M, et al. Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases. Mod Pathol 2003 May; 16 (5): 512-4
30. Mimouni D, Anhalt GJ, Cummins DL, et al. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol 2003; 139: 739-42
31. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006 Nov; 142 (11): 1447-54
32. Baum S, Scope A, Barzilai A, et al. The role of IVIg treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol 2006 May; 20 (5): 548-52
33. Cooper HL, Healy E, Theaker JM, et al. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol 2003 Jul; 28 (4): 366-8
34. Renkl A, Mockenhaupt M, Technau K, et al. A novel therapeutic option in pemphigus vulgaris: humanized monoclonal anti-CD25 antibody. Br J Dermatol 2005; 150: 1212-34
35. Pardo J, Mercader P, Mahiques L, et al. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005; 153 (1): 222-3
36. Berookhim BR, Fisher HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor antagonist etanercept. Cutis 2004; 74 (4): 245-7